Joint Damage Is Inhibited With Enbrel® (Etanercept) Plus Methotrexate In Patients With Early Active Rheumatoid Arthritis

Data presented recently show that 80% of patients with early active rheumatoid arthritis achieved radiographic remission (or non-progression defined as a change in TSS up to and including 0.5) at one year when treated with Enbrel (etanercept) and methotrexate, compared to 59% when treated with methotrexate alone1. COMET* (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) is the first major trial to use remission as its primary endpoint in patients with early active rheumatoid arthritis treated with a biologic. Data from the landmark COMET study were presented at the European League Against Rheumatism (EULAR) Annual Meeting in Paris.



The COMET trial also showed that 50% of patients taking the Enbrel plus methotrexate combination achieved clinical remission (DAS28